BrainPlotting

BrainPlotting is a French contract research organization specialized in predicting the entrance of drugs into the human brain during preclinical stages. The company, incubated at the Brain and Spine Institute (ICM) in Paris, was founded in 2013. BrainPlotting's core business revolves around studying pharmacokinetics (PK) in the human brain, particularly focusing on molecules with central nervous system (CNS) targets as well as peripheral targets.

Utilizing in vitro models based on primary human cells, BrainPlotting employs the most accurate predictive models and the latest methods to generate high-accuracy predictions. Their expertise allows for PK predictions at different stages of molecule development such as screening, Hit-to-Lead, and lead optimization. The methods employed include evaluating blood-brain barrier permeability, determining the unbound fraction of the drug in the blood and brain, estimating drug concentration in the brain, and modeling human in vivo concentration based on human in vitro data.

Recently, BrainPlotting secured a Seed Round investment from Starquest Capital on September 15, 2014. As a company operating in the Health Care industry and based in France, BrainPlotting's innovative approach to predicting drug entry into the human brain presents a compelling opportunity for investors seeking to participate in the advancement of pharmaceutical research and development.